Regarding the role of Super-enhancers in development of breast cancer, it has been reported that the oncogenes: human epidermal growth receptor 2 (ERBB2), hepatocyte growth factor receptor (MET), MYC, nuclear receptor coactivator A3 (NCOA3), neurogenic locus notch homolog protein 2 (NOTCH2) and Runt-related transcription factor 1 (RUNX1) are part of specific expression scheme that is induced by this new regulatory regions for the acquisition of the malignant phenotype [30]. The gene discussed is MET; the disease is breast cancer.